226 related articles for article (PubMed ID: 17477363)
1. Inhibition of fatty acid synthase activity in prostate cancer cells by dutasteride.
Schmidt LJ; Ballman KV; Tindall DJ
Prostate; 2007 Jul; 67(10):1111-20. PubMed ID: 17477363
[TBL] [Abstract][Full Text] [Related]
2. Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines.
Maria McCrohan A; Morrissey C; O'Keane C; Mulligan N; Watson C; Smith J; Fitzpatrick JM; Watson RW
Cancer; 2006 Jun; 106(12):2743-52. PubMed ID: 16703599
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers.
Xu Y; Dalrymple SL; Becker RE; Denmeade SR; Isaacs JT
Clin Cancer Res; 2006 Jul; 12(13):4072-9. PubMed ID: 16818707
[TBL] [Abstract][Full Text] [Related]
4. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
5. KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells.
Lee MY; Moon JS; Park SW; Koh YK; Ahn YH; Kim KS
Biochem J; 2009 Jan; 417(1):313-22. PubMed ID: 18774944
[TBL] [Abstract][Full Text] [Related]
6. Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells.
Thelen P; Schweyer S; Hemmerlein B; Wuttke W; Seseke F; Ringert RH
Int J Oncol; 2004 Jan; 24(1):25-31. PubMed ID: 14654937
[TBL] [Abstract][Full Text] [Related]
7. Fatty acid synthase gene overexpression and copy number gain in prostate adenocarcinoma.
Shah US; Dhir R; Gollin SM; Chandran UR; Lewis D; Acquafondata M; Pflug BR
Hum Pathol; 2006 Apr; 37(4):401-9. PubMed ID: 16564913
[TBL] [Abstract][Full Text] [Related]
8. Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer.
Andriole GL; Humphrey P; Ray P; Gleave ME; Trachtenberg J; Thomas LN; Lazier CB; Rittmaster RS
J Urol; 2004 Sep; 172(3):915-9. PubMed ID: 15310997
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of fatty acid synthase expression in colorectal cancers in Middle Eastern patients and its potential role as a therapeutic target.
Uddin S; Hussain AR; Ahmed M; Abubaker J; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Bavi P; Al-Kuraya KS
Am J Gastroenterol; 2009 Jul; 104(7):1790-801. PubMed ID: 19491830
[TBL] [Abstract][Full Text] [Related]
10. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
[TBL] [Abstract][Full Text] [Related]
11. Effects of dutasteride on prostate growth in the large probasin-large T antigen mouse model of prostate cancer.
Shao TC; Li H; Ittmann M; Cunningham GR
J Urol; 2007 Oct; 178(4 Pt 1):1521-7. PubMed ID: 17707058
[TBL] [Abstract][Full Text] [Related]
12. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells.
Brusselmans K; De Schrijver E; Verhoeven G; Swinnen JV
Cancer Res; 2005 Aug; 65(15):6719-25. PubMed ID: 16061653
[TBL] [Abstract][Full Text] [Related]
13. Increased fatty acid synthase as a therapeutic target in androgen-independent prostate cancer progression.
Pizer ES; Pflug BR; Bova GS; Han WF; Udan MS; Nelson JB
Prostate; 2001 May; 47(2):102-10. PubMed ID: 11340632
[TBL] [Abstract][Full Text] [Related]
14. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride.
Musquera M; Fleshner NE; Finelli A; Zlotta AR
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452
[TBL] [Abstract][Full Text] [Related]
15. Analyzing effects of extra-virgin olive oil polyphenols on breast cancer-associated fatty acid synthase protein expression using reverse-phase protein microarrays.
Menendez JA; Vazquez-Martin A; Oliveras-Ferraros C; Garcia-Villalba R; Carrasco-Pancorbo A; Fernandez-Gutierrez A; Segura-Carretero A
Int J Mol Med; 2008 Oct; 22(4):433-9. PubMed ID: 18813848
[TBL] [Abstract][Full Text] [Related]
16. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75.
Puig T; Vázquez-Martín A; Relat J; Pétriz J; Menéndez JA; Porta R; Casals G; Marrero PF; Haro D; Brunet J; Colomer R
Breast Cancer Res Treat; 2008 Jun; 109(3):471-9. PubMed ID: 17902053
[TBL] [Abstract][Full Text] [Related]
17. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
[TBL] [Abstract][Full Text] [Related]
18. The effects of the dual 5alpha-reductase inhibitor dutasteride on localized prostate cancer--results from a 4-month pre-radical prostatectomy study.
Gleave M; Qian J; Andreou C; Pommerville P; Chin J; Casey R; Steinhoff G; Fleshner N; Bostwick D; Thomas L; Rittmaster R
Prostate; 2006 Nov; 66(15):1674-85. PubMed ID: 16927304
[TBL] [Abstract][Full Text] [Related]
19. The dual 5-alpha-reductase inhibitor dutasteride induces atrophic changes and decreases relative cancer volume in human prostate.
Iczkowski KA; Qiu J; Qian J; Somerville MC; Rittmaster RS; Andriole GL; Bostwick DG
Urology; 2005 Jan; 65(1):76-82. PubMed ID: 15667867
[TBL] [Abstract][Full Text] [Related]
20. Thiazolidinediones/PPARγ agonists and fatty acid synthase inhibitors as an experimental combination therapy for prostate cancer.
Mansour M; Schwartz D; Judd R; Akingbemi B; Braden T; Morrison E; Dennis J; Bartol F; Hazi A; Napier I; Abdel-Mageed AB
Int J Oncol; 2011 Feb; 38(2):537-46. PubMed ID: 21170507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
